Evidence method
Level · gp.fundamentals.capex_revenue_ratio
51.47% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Sep 30, 2019
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-19-000005General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-260.68% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
3286.23% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
77.88% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
92.56% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-308.73% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
229.51% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
65.67% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History17 statesSelf-history eligible
Sep 30, 20180/7 normalizedLevel 3Dec 31, 20180/7 normalizedLevel 3Mar 31, 20190/7 normalizedLevel 3Jun 30, 20190/8 normalizedLevel 3Sep 30, 20190/8 normalizedLevel 3Dec 31, 20190/8 normalizedLevel 3Mar 31, 20200/8 normalizedLevel 3Jun 30, 20204/8 normalizedLevel 3Sep 30, 20207/8 normalizedLevel 3Dec 31, 20207/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Sep 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 47.51%
- Current
- 51.47%
- Delta
- 3.96%
- Previous
- 645.65%
- Current
- -260.68%
- Delta
- -906.32%
- Previous
- 49.51%
- Current
- 3286.23%
- Delta
- 3236.72%
- Previous
- 90.77%
- Current
- 77.88%
- Delta
- -12.89%
- Previous
- 90.33%
- Current
- 92.56%
- Delta
- 2.23%
- Previous
- -528.40%
- Current
- -308.73%
- Delta
- 219.68%
- Previous
- 366.53%
- Current
- 229.51%
- Delta
- -137.02%
- Previous
- 68.44%
- Current
- 65.67%
- Delta
- -2.77%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_INCREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_INCREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.